What, if anything, does your unit do to reduce noise levels in the ICU?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to B Schuessler.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Sulprostone, a new prostaglandin E2-derivative, with high selectivity for the uterine muscle, was tested in 180 women (62 primigravidae) for induction of abortion in the first trimester of pregnancy by intramuscular administration. Total dosages from 500 to 1,500 mcg in single injections of 500 mcg were tested. The injections were given at intervals of 4 to 8 hours. Adequate cervical dilatation was achieved in nearly 94% of the patients with complete abortion in more than 50%. No sulprostone-related complications such as shock or cramps were registered. Side effects were at a tolerable level with concomitant medication being necessary for about one-third of the patients. Optimal effectiveness and acceptability were recorded, at an injection interval of 6 to 8 h and a total dose of 1,000 mcg sulprostone. The application of sulprostone as abortifacient in first trimester pregnancy is discussed.
Explore the source record for details and available documents.
The abortifacient effect of a new tissue-selective prostaglandin E2-derivative, sulprostone, administered intravenously, has been investigated in 166 women in the the first trimester of pregnancy. Four different dose schedules (1.7 mcg/min for 5 or 10 hour--total dose 500 mcg or 1000 mcg, 2.8 mcg/min and 4.1 mcg/min for 6 hours--total dose 1000 mcg and 1500 mcg) have been evaluated. No absolute failures occurred and no severe complications or side-effects were recorded. Best results (high abortifacient efficacy and low systemic side-effects) were obtained by infusing 1000 mcg sulprostone in appr. 10 h. Our study indicates that sulprostone appears to have a high degree of acceptability.